Literature DB >> 26002751

Oncologic results and prognostic predictors of patients with locally advanced rectal cancer showing ypN0 after radical surgery following neoadjuvant chemoradiotherapy.

Kyung-Ha Lee1, Jae-Chan Kim, Ji-Yeon Kim, Jin-Su Kim.   

Abstract

PURPOSE: Adjuvant chemotherapy is recommended for patients with locally advanced rectal cancer after radical surgery following neoadjuvant chemoradiotherapy (NCRT) regardless of the final pathologic stage. However, the efficacy of adjuvant chemotherapy in ypN0 patients remains controversial. The aim of this study was to evaluate the oncologic outcomes and analyze the prognostic factors for ypN0 patients in order to estimate prognosis and establish an effective adjuvant chemotherapy strategy for stage 0-II rectal cancers after radical surgery following NCRT.
METHODS: Between January 1999 and December 2009, the medical records of 202 patients who had been diagnosed with locally advanced rectal cancer, underwent radical surgery following NCRT, and showed ypN0 were retrospectively reviewed.
RESULTS: The median follow-up period was 60.5 months. The 5-year local recurrence rate was 3.1 %. The 5-year disease-free survival and 5-year overall survival were 86.3 and 86.9 %. Postirradiation T3-4 and abdominoperineal resection (APR) were the independent prognostic indicators for disease-free survival (p = 0.001, p = 0.003) and overall survival (p = 0.001, p = 0.002). Adjuvant chemotherapy improved local recurrence in the patient with ypT3-4 and patients who had undergone APR (p = 0.014, p = 0.002). APR affected local recurrence, disease-free survival, and overall survival of ypT3-4 patients (p = 0.013. 0.029, and 0.001)
CONCLUSIONS: Postirradiation T3-4 and APR are the significant prognostic factors for ypN0. Further randomized prospective study is needed to evaluate the oncologic benefit of adjuvant chemotherapy in ypN0 patients, especially those with ypT3-4 and those having undergone APR, and to confirm which chemotherapeutic agent could improve the oncologic outcomes of patients poorly responding to NCRT.

Entities:  

Mesh:

Year:  2015        PMID: 26002751     DOI: 10.1007/s00384-015-2261-3

Source DB:  PubMed          Journal:  Int J Colorectal Dis        ISSN: 0179-1958            Impact factor:   2.571


  21 in total

1.  Chemotherapy with preoperative radiotherapy in rectal cancer.

Authors:  Jean-François Bosset; Laurence Collette; Gilles Calais; Laurent Mineur; Philippe Maingon; Ljiljana Radosevic-Jelic; Alain Daban; Etienne Bardet; Alexander Beny; Jean-Claude Ollier
Journal:  N Engl J Med       Date:  2006-09-14       Impact factor: 91.245

2.  Prognostic value of pathologic complete response after neoadjuvant therapy in locally advanced rectal cancer: long-term analysis of 566 ypCR patients.

Authors:  Carlo Capirci; Vincenzo Valentini; Luca Cionini; Antonino De Paoli; Claus Rodel; Robert Glynne-Jones; Claudio Coco; Mario Romano; Giovanna Mantello; Silvia Palazzi; Falchetti Osti Mattia; Maria Luisa Friso; Domenico Genovesi; Cristiana Vidali; Maria Antonietta Gambacorta; Alberto Buffoli; Marco Lupattelli; Maria Silvia Favretto; Giuseppe La Torre
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-04-11       Impact factor: 7.038

3.  Nomograms for predicting local recurrence, distant metastases, and overall survival for patients with locally advanced rectal cancer on the basis of European randomized clinical trials.

Authors:  Vincenzo Valentini; Ruud G P M van Stiphout; Guido Lammering; Maria Antonietta Gambacorta; Maria Cristina Barba; Marek Bebenek; Franck Bonnetain; Jean-Francois Bosset; Krzysztof Bujko; Luca Cionini; Jean-Pierre Gerard; Claus Rödel; Aldo Sainato; Rolf Sauer; Bruce D Minsky; Laurence Collette; Philippe Lambin
Journal:  J Clin Oncol       Date:  2011-07-11       Impact factor: 44.544

4.  Analysis of clinical outcomes and prognostic factors of neoadjuvant chemoradiotherapy combined with surgery: intraperitoneal versus extraperitoneal rectal cancer.

Authors:  E Benzoni; G Terrosu; V Bresadola; F Cerato; A Cojutti; E Milan; G Dado; F Bresadola
Journal:  Eur J Cancer Care (Engl)       Date:  2006-07       Impact factor: 2.520

Review 5.  Does adjuvant fluoropyrimidine-based chemotherapy provide a benefit for patients with resected rectal cancer who have already received neoadjuvant radiochemotherapy? A systematic review of randomised trials.

Authors:  K Bujko; R Glynne-Jones; M Bujko
Journal:  Ann Oncol       Date:  2010-03-15       Impact factor: 32.976

6.  Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.

Authors:  Jean-Pierre Gérard; Thierry Conroy; Franck Bonnetain; Olivier Bouché; Olivier Chapet; Marie-Thérèse Closon-Dejardin; Michel Untereiner; Bernard Leduc; Eric Francois; Jean Maurel; Jean-François Seitz; Bruno Buecher; Rémy Mackiewicz; Michel Ducreux; Laurent Bedenne
Journal:  J Clin Oncol       Date:  2006-10-01       Impact factor: 44.544

7.  Local recurrence of low rectal cancer after abdominoperineal and anterior resection.

Authors:  E Rullier; C Laurent; J Carles; J Saric; P Michel; M Parneix
Journal:  Br J Surg       Date:  1997-04       Impact factor: 6.939

8.  Predictive factors of positive circumferential resection margin after radiochemotherapy for rectal cancer: the French randomised trial ACCORD12/0405 PRODIGE 2.

Authors:  Anne Rullier; Sophie Gourgou-Bourgade; Marta Jarlier; Frédéric Bibeau; Catherine Chassagne-Clément; Christophe Hennequin; Laurent Tisseau; Agnès Leroux; Francette Ettore; Michel Peoc'h; Marie-Agnès Diebold; Yves-Marie Robin; Isabelle Kleinclaus; Laurent Mineur; Christophe Petitjean; Jean-François Mosnier; Isabelle Soubeyran; Norbert Padilla; Anne-Isabelle Lemaistre; Jocelyne Bérille; Bernard Denis; Thierry Conroy; Jean-Pierre Gérard
Journal:  Eur J Cancer       Date:  2012-08-18       Impact factor: 9.162

9.  Is final TNM staging a predictor for survival in locally advanced rectal cancer after preoperative chemoradiation therapy?

Authors:  Li-Jen Kuo; Mei-Ching Liu; James Jer-Min Jian; Cheng-Fang Horng; Tsun-I Cheng; Chung-Ming Chen; Wei-Tse Fang; Yih-Lin Chung
Journal:  Ann Surg Oncol       Date:  2007-06-06       Impact factor: 5.344

10.  Patients with curative resection of cT3-4 rectal cancer after preoperative radiotherapy or radiochemotherapy: does anybody benefit from adjuvant fluorouracil-based chemotherapy? A trial of the European Organisation for Research and Treatment of Cancer Radiation Oncology Group.

Authors:  Laurence Collette; Jean-Francois Bosset; Marcel den Dulk; France Nguyen; Laurent Mineur; Philippe Maingon; Ljiljana Radosevic-Jelic; Marianne Piérart; Gilles Calais
Journal:  J Clin Oncol       Date:  2007-10-01       Impact factor: 44.544

View more
  3 in total

1.  Oncologic effects of adjuvant chemotherapy in patients with ypT0-2N0 rectal cancer after neoadjuvant chemoradiotherapy and curative surgery: a meta-analysis.

Authors:  Gi Won Ha; Min Ro Lee
Journal:  Ann Surg Treat Res       Date:  2020-07-31       Impact factor: 1.859

2.  Is adjuvant chemotherapy necessary for patients with ypT0-2N0 rectal cancer treated with neoadjuvant chemoradiotherapy and curative surgery?

Authors:  Zhao Lu; Pu Cheng; Ming-Guang Zhang; Xi-Shan Wang; Zhao-Xu Zheng
Journal:  Gastroenterol Rep (Oxf)       Date:  2018-08-13

3.  Rectal cancer patients with downstaging after neoadjuvant chemoradiotherapy and radical resection do not benefit from adjuvant chemotherapy.

Authors:  Hang Zhang; Ya Huang; Ge Sun; Kuo Zheng; Zheng Lou; Xian-Hua Gao; Li-Qiang Hao; Lian-Jie Liu; Rong-Gui Meng; Wei Zhang
Journal:  Ann Transl Med       Date:  2020-06
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.